Wellgistics Health prices $5 million public offering at $0.70 per share

TAMPA - Wellgistics Health, Inc. (NASDAQ:WGRX), currently trading at $1.01 with a market capitalization of $72.7 million, has priced a public offering of 7,142,862 shares of common stock with accompanying warrants at $0.70 per share and associated warrant, according to a press release statement.

The pharmaceutical distribution company said the warrants will have an exercise price of $0.70 per share, will be immediately exercisable upon issuance, and will expire after five years.

The offering, expected to close around September 29, 2025, aims to raise approximately $5 million in gross proceeds before deducting placement agent fees and other offering expenses.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction.

Wellgistics Health intends to use the net proceeds for working capital and general corporate purposes, including operating expenses, research and development, and potential acquisitions.

The Securities and Exchange Commission declared effective a registration statement on Form S-1 related to the offering on September 25, 2025.

Wellgistics Health operates an integrated platform connecting over 6,500 independent pharmacies and more than 200 U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-driven hub services. The company generated revenue of $36.7 million in the last twelve months, though operating with a slim gross profit margin of 8.1%. InvestingPro subscribers can access 8 additional key insights about WGRX’s financial performance and future outlook.

The company noted that the offering is being made only through a prospectus forming part of the effective registration statement, with electronic copies of the final prospectus to be available on the SEC’s website.

In other recent news, Wellgistics Health, Inc. has taken significant steps to improve its financial standing. The company announced the conversion of $8.1 million in debt to equity, a move aimed at reducing short-term debt obligations and strengthening its financial position. Additionally, Wellgistics Health has launched an XRP Implementation Program to enable independent pharmacies to process blockchain-based payments, promising lower fees and instant transactions. In a strategic shift, the company terminated its equity purchase agreement with Hudson Global Ventures, opting for what it calls more accretive financing options. Furthermore, Wellgistics Health has made a change in its auditing firm, appointing UHY LLP as the new auditor after dismissing Suri & Co. The previous auditor had noted concerns about the company’s ability to continue as a going concern, though their reports did not contain adverse opinions. These developments reflect Wellgistics Health’s efforts to optimize its financial structure and operational processes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.